SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies informs about press release

22 Jun 2023 Evaluate

Venus Remedies has informed that it enclosed a press release being issued by the Company on 22nd June, 2023 titled ‘Venus Remedies Bags approval to Market Meropenem, its Blockbuster Generic Drug, in Spain’.

The above information is a part of company’s filings submitted to BSE.

Venus Remedies Share Price

975.65 -30.95 (-3.07%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×